A double-blind trial of feprazone in osteoarthritis of the hip.

Abstract

A double-blind crossover study was carried out in 21 patients with osteoarthrosis of the hip to compare the efficacy and tolerance of feprazone (600 mg/day) and ibuprofen (1200 mg/day), each drug being given for 4 weeks. No statistically significant changes were noted in any of the objective parameters measured, but patients' subjective assessments of pain showed a significant improvement in pain levels (p less than or equal to 0.05, day and night) after feprazone. One patient, who had reported a rash at initial assessment, was withdrawn at the end of the first treatment period (on feprazone) when he developed a severe rash, 1 patient was withdrawn because of exacerbation of symptoms (on ibuprofen) and a further patient was lost to follow-up because of intercurrent illness. Both drugs were well tolerated by the other patients and the few side-effects reported were minor in nature.

• Authors: L S Bain, M P Lynch, G M Bruce
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 4 Issue 9 Pg. 665-9 ( 1977) ISSN: 0300-7995 [Print] England
• PMID: 338255 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Feprazone
• Phenylbutazone
• Ibuprofen

Topics

• Aged
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Feprazone (adverse effects, therapeutic use)
• Hip Joint
• Humans
• Ibuprofen (adverse effects, therapeutic use)
• Male
• Middle Aged
• Osteoarthritis (drug therapy)
• Pain
• Phenylbutazone (analogs & derivatives)